Ask Our Experts April 27, 2023 What to Know About a “Breakthrough” Weight Loss Drugs The drugs, Wegovy® and Ozempic® have been in the news and trending on social media due to their unprecedented success in helping people lose large amounts of weight. Our experts at PHM answer some common questions about the recently FDA approved drug, Wegovy. Read More
Published Research April 27, 2023 Actions for employers to mitigate cancer risk Advancements in cancer care over the past 20 years have been transformational, driven by updated recommendations in cancer screening, emergence of molecular diagnostic tools to guide treatments, and the development of cutting-edge therapeutics. Each offers the potential for better outcomes, but employers are faced with the challenge of ensuring these often costly tools and treatments are used effectively. In the newly published whitepaper, "Managing Cancer Care in Your Health Plan," Private Health Management (PHM) and Springbuk experts provide insights for employers to improve cancer outcomes and optimize cancer spend. Download the whitepaper now. Read More
News April 26, 2023 Employers can play a significant role in closing the clinical quality gap in cancer In the 2023 "Managing Cancer Care in Your Health Plan" whitepaper, PHM brings clinical insights to Springbuk's claims data from more than 1,000 select employers consisting of 1.7 million lives covered. The paper identifies three areas of opportunities for companies to: Encourage prevention through advanced screenings to achieve better health outcomes at lower treatment costs. Enable molecular profiling, still highly underutilized, to ensure cancers are appropriately characterized and individuals are benefiting from the latest in precision medicine. Optimize drug spend by making informed formulary decisions, not merely restricting use of high-cost drugs. Read More
Podcasts April 17, 2023 Sophisticated Solutions for Complex Cancer Care In the latest episode of the Springbuk podcast, Natalya Gertsik, Ph.D., Vice President, ClearCancer Solution Management, at Private Health Management, and a contributor to the 2023 Springbuk Employee Health Trends report, joins Jennifer Jones and Mike Pattengale to chat through sophisticated solutions for complex cancer care. Read More
Published Research January 26, 2023 An Inside Look at Employee Health Trends PHM is pleased to be a contributing partner to Springbuk’s 2023 Employee Health Trends report. The newly released report provides recommendations that will impact how benefits leaders plan, deliver, and evaluate employee benefits programs. Effects of COVID-19 on costs and health Surges in cancer costs Specialty drug use Telemedicine & mental health services Dr. Natalya Gertsik, PHM’s Vice President, ClearCancer Solution Management, offers key insights on earlier cancer detection, improving outcomes, and reducing cancer-related spending. Read More
Ask Our Experts January 26, 2023 FDA Approves New Alzheimer’s Treatment: What to know About Leqembi® (lecanemab) Leqembi® (lecanemab) was approved to treat Alzheimer’s disease in January, 2023 under the FDA’s Accelerated Approval process for diseases with an unmet need for treatment.1 The manufacturers, Eisai pharmaceuticals, plan to submit data for full FDA approval by the end of March 2023. Here, we answer some common questions about Leqembi and summarize what is known about its safety and effectiveness. Patients and their families should speak with their physician and weigh the potential benefits and risks before deciding whether to seek treatment with Leqembi. Read More
